Identifying early detection biomarkers for ovarian cancer using blood samples
Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls
['FUNDING_U01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-10907763
This study is looking for specific proteins in the blood that could help spot ovarian cancer early, by comparing samples from women with the disease to those from healthy women, so we can improve how we detect this cancer sooner.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10907763 on ClinicalTrials.gov |
What this research studies
This research focuses on discovering and validating plasma biomarkers that can indicate the early presence of ovarian cancer. By analyzing blood samples from individuals diagnosed with ovarian cancer and comparing them to samples from healthy controls, the study aims to identify specific proteins that show significant changes over time in cancer patients while remaining stable in healthy individuals. The methodology involves advanced proteomic assays that require minimal blood volume, making it feasible to use samples collected over long periods. This approach leverages the unique growth patterns of cancer to enhance early detection efforts.
Who could benefit from this research
Good fit: Ideal candidates for this research include women at high risk for ovarian cancer or those with a family history of the disease.
Not a fit: Patients who are not at risk for ovarian cancer or who have already been diagnosed with advanced-stage ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis of ovarian cancer, improving treatment outcomes and survival rates for patients.
How similar studies have performed: Previous research has shown promise in using proteomic approaches for cancer biomarker discovery, indicating potential for success in this novel application.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SKATES, STEVEN J — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: SKATES, STEVEN J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.